

# imp**act g**enetics

# **Uveal Melanoma**

Prognostic Genetic Test Submission Guide







Impact Genetics 115 Midair Court Brampton, ON L6T 5M3 1-877-624-9769

# Results





# Form 1a: Informed Consent to Perform Genetic Testing for Uveal Melanoma

The purpose of my DNA test is to look for mutation(s) or genetic alterations known to be associated with prognosis for survival in patients with uveal melanoma. I understand this test requires tumor and blood (or other normal) samples for use in prognostic testing.

#### By signing below, I acknowledge that:

- 1. My participation in this DNA testing is voluntary. The decision to consent to, or to refuse the above testing is entirely mine.
- 2. This testing is done on small biological samples.
- 3. It is possible that the quantity or quality of sample submitted may be inadequate for testing.
- 4. I understand that prognostic genetic tests for uveal melanoma are not entirely predictive. Patients with a good prognosis can develop metastatic disease (albeit rarely) and vice versa.
- 5. Impact Genetics will disclose the test results ONLY to the specialist designated on the Requisition Form (*Form 1b*), or to his/her agent, unless otherwise authorized by the patient or required by law, except as described in point 11 below, no information will be printed or released that discloses the patient's identity, or other confidential information.
- 6. Impact Genetics is not a DNA banking facility and patient DNA samples may not be available for future testing.
- 7. There is a chance that the test may reveal unexpected abnormalities that may be of medical value in the patient's care. Impact Genetics will inform the referring specialist designated below.
- 8. Until the results of this test are reported, the patient should still undergo examinations as prescribed by the referring specialist.
- 9. If necessary to obtain reimbursement of test fees, Impact Genetics, its agents and legal representatives may disclose information that identifies the patient or other confidential information (including test results).
- 10. I have read or have had read to me, the above information and I understand it. I have also read or had explained to me the specific disease or condition tested for, and the specific test(s) I am having, including the test descriptions, principles and limitations. I have had the opportunity to discuss the purposes and possible risks of this testing with my doctor or someone my doctor has designated.

|    | Consent for Future Research:  After all analysis required to reach a genetic diagnosis is complete, Impact Genetics has my consent to use any surplus DNA in an anonymous fashion for research.  YES DNO   |  |  |  |  |
|----|--|--|--|--|--|
|    | Consent to Contact Family:  I understand that information about my clinical health status will further improve the power of this prognostic uveal melanoma test for the benefit of future patients. I permit Impact Genetics (Dynacare) to contact me or members of my family for updated information about my health. |  |  |  |  |
|    | □ YES □ NO   |  |  |  |  |
|    | Contact Information:   |  |  |  |  |
|    | Name:  |  |  |  |  |
|    | Telephone:Email:   |  |  |  |  |
|    | Alternate Contact Information:  Name: Telephone: Email:  |  |  |  |  |
| •  |  |  |  |  |  |
| Si | gnature of Patient:Date:   |  |  |  |  |
|    |  |  |  |  |  |
| Si | inature of Witness:  |  |  |  |  |



| LAB USE ONLY DO NOT FILL OUT |   |       |  |  |  |
|------------------------------|---|-------|--|--|--|
| Date received: Y             | M | D     |  |  |  |
| Specimen type:               |   |       |  |  |  |
| Condition:                   |   |       |  |  |  |
| MRN:                         |   | Tech: |  |  |  |

# Form 1b: Uveal Melanoma Prognostic Genetic Test Requisition

| Ordering Options   | Patient History  |
|--|--|
| ☐ Uveal Melanoma Prognostic Genetic Test   | Diagnosis date: Y M D  |
| ▶ For BAP 1 Germline Analysis -Complete a BAP1 Test Requisition  | Type of primary management:  □ None □ Proton beam radiotherapy □ Enucleation   |
| Patient  | ☐ Plaque therapy ☐ Other:  |
| Last name:   | Date: Y M D  |
| First name:  |  |
| Date of birth: Y M D   | Referring Specialist   |
| Gender:   Male   Female  | Name:  |
| Ethnicity:   | Specialty:   |
| Pigmentation:  | Contact:   |
| Skin color:Hair color:   | Telephone:Fax:   |
| Eye color:   | Email:   |
| Specimen Information   | Signature:   |
| Tumor collection method:   |  |
| ☐ FNAB ☐ Enucleation ☐ Surgical resection  | Institution:   |
| ☐ Other:   | Address:   |
| Tumor sample (required):   |  |
| ☐ Fresh tumor in cell lysis (Impact Genetics collection tube)  | City:Prov/State:   |
| ☐ Frozen tumor ☐ To follow (sending separately)  | Postal code:Country:   |
| □ DNA from tumor □ Other:  | Additional copies to:  |
| Date of collection: Y M D  | Email:Fax:   |
| Time of collection: HH:MM (24hr)   | i Billing  |
| Normal/control sample (required):  |  |
| ☐ Buccal swab (UM Prognostic Test only) ☐ Blood (UM Prognostic Test and <i>BAP1</i> Germline Analysis)   | Impact Genetics tests ordered through LabCorp test menu.  USA only.  |
| Date of collection: Y M D  |  |
| Time of collection: HH:MM (24hr)   | Provide details:   |
| Time of concedion,   |  |
| Histology  |  |
| Tumor thickness* (by ultrasound, mm):  |  |
| Largest basal tumor diameter** (LBD, mm):  |  |
| Anatomic sub-classification:   | $\square$ b) Patient Pay   |
| □ Choroid □ Iris □ Ciliary body involvement  | Complete <b>LabCorp Financial Responsibility Form</b> .  |
| Other:   | ☐ c) Third party insurance (USA only)  |
| <b>Extraocular extension</b> (spread) <b>present:</b> □Yes □No   | Complete Form 1c: U.S. Insurance Information and to expedite testing, complete LabCorp Financial Responsibility Form.                |
| Mitotic count:perHPF   | • testing, complete <b>Luocorp i municial nesponsionity i offi</b> .   |
| Closed loops: ☐Yes ☐ No  | Ordering Specialist: By submitting this form, I confirm that   |
| Predominant cellular classification:   | this test is being ordered for the purpose of prognosis as per the<br><b>Laboratory and Specimen Collection Centre Licensing Act</b> |
| ☐ Pure spindle ☐ Predominantly spindle ☐ Epitheloid  | (Ontario, Canada).   |
| ☐ Predominantly epitheloid ☐ Unknown   |  |
| Necrosis: ☐Yes ☐ No  | 115 Midair Court, Brampton, ON L6T 5M3   |
| AJCC TNM stage:  ** There yoll us are sequired for TNM surplyorship prediction   | t: 647-478-4902 or 1-877-624-9769 f: 905-697-9786<br>e: info@impactgenetics.com <u>Please ensure to use secure email</u>             |
| ** The second of | 6. ITTO CATT PACKY ETTERICS. COTT  |



## Form 1c: U.S. Insurance Information

Impact Genetics is committed to providing the highest quality genetic testing to all patients. In many situations, genetic testing improves outcomes and quality of life and decreases total costs to the patient and healthcare system.

Processing medical insurance claims is usually challenging and time consuming. Many insurance companies require pre-authorization prior to testing. Impact Genetics supports insurance billing, completing coverage checks and pre-authorization.

It is important for patients to understand that insurance rarely covers 100% of the cost of genetic testing and that they will be financially responsible for some or all of the cost of testing. The patient is responsible for any portion of the test fee not covered by insurance for any reason, including but not limited to, co-payments, unmet deductibles, co-insurance and non-covered services. Prior determinations do not guarantee payment and the amount paid by insurance when the claim is submitted may be different from the coverage indicated during the pre-verification or pre-authorization process.

Pre-authorizations can take time to obtain depending on each individual insurance plan's policy and documentation requirements. Turnaround time for test results begins after the pre-authorization has been processed and approved.

For tests ordered through LabCorp, LabCorp administers billing. The LabCorp prior-authorization team will file a pre-verification/prior-authorization on behalf of the patient with any commercial insurance company. State managed Medicare plans cannot be billed.

#### Insurance process

- 1. Send Form 1c: U.S. Insurance Information as soon as possible.
- 2. Send LabCorp Financial Responsibility Form to initiate testing immediately.
- 3. Insurance coverage will be investigated and patient/specialist will be contacted to provide coverage estimate if the patient's out of pocket costs are over \$300.00.
- 4. Insurance claim will be submitted upon completion of testing.
- 5. After insurance payment is received patient will be billed for non-covered services.

**Note:** Timely and complete submissions will enable faster insurance checks.



# Send this form to LabCorp BY FAX TO 1-888-598-7568

Form 1c: U.S. Insurance Information - Uveal Melanoma

| Disease /Genetic Test   | Patient Information  |  |  |
|---|--|--|--|
| □ <b>Test # 480344 -</b> Uveal melanoma   | Last name:   |  |  |
| ICD-10 Code <i>•• provide code here ••</i> ▶  | First name:  |  |  |
| CPT Codes: 81294, 81403, 81406, 81479, 81301  | Date of birth: Y M D   |  |  |
| Insurance Information  □ Primary insurance □ Secondary insurance  If Patient has secondary insurance, include the information on an additional copy of this form with the secondary | Address:   |  |  |
| insurance box checked.  Name of insured (if not Patient):   | State:Zip code: Country:   |  |  |
|   | Telephone:   |  |  |
| Insurance company:  Claims address:   | Contact Information  Details of insurance coverage will be communicated.  Please provide preferred telephone number(s):                  |  |  |
| City:   | ☐ Patient ☐ Referring specialist   |  |  |
| State:Zip code:   | Telephone:   |  |  |
| Country:  | Alternate telephone:   |  |  |
| Group #:  | Email:   |  |  |
| Subscriber/member #:  | ☐ In the event Patient cannot be reached a voice message related to uveal melanoma genetic testing may be left at                        |  |  |
| Physician Information   | the above phone number(s)  |  |  |
| Physician's name:   | Flease Allach All of the Following   |  |  |
| Practice name: Practice Address:  | <ul> <li>Letter of Medical Necessity, signed by Referring<br/>Specialist (contact Impact Genetics for template<br/>if needed)</li> </ul> |  |  |
| Telephone:  | <ul> <li>Clinic notes demonstrating the Patient's need for<br/>testing and confirmation of diagnosis</li> </ul>                          |  |  |
| Fax:  | $\bullet$ Insurance approval details $\emph{if}$ prior pre-approval completed  |  |  |
| LabCorp account #:  | Performing Lab - Impact Genetics   |  |  |

Testing process will be initiated when **LabCorp Financial Responsibility Form** is received or confirmation is received from insurance provider. Brampton, ON L6T 5M3 CANADA

t: 1-877-998-7837 f: 1-888-598-7568

e: preverification@labcorp.com Please ensure to use secure email

# LabCorp Statement of Financial Responsibility

| S   | section A: Member/Patient Informa  | tion   |                                     |                              |
|-----|--|--|-------------------------------------|------------------------------|
| Me  | ember/patient name:  |  | / Date of birth                     | n:                           |
|     |  |  |                                     |                              |
| Cit | y:   |  | / ST: /                             | ZIP:                         |
|     |  | / Client account #:  |                                     |                              |
| Sul | oscriber #:  |  |                                     |                              |
| S   | Section B: Requested procedure or s  | service information  |                                     |                              |
| Bas |  | urance plan, your plan is <b>not expected to pa</b>  | y 100% for the laboratory tes       | t(s) ordered by your         |
|     | Test/CPT Description   | Reason for Patient Out of Po   | ocket                               | Estimated Cost*              |
|     |  |  |                                     |                              |
|     | tal Estimated Patient Responsibility*:<br>*<br>ext Steps:                              | This is only an estimate. Actual amount owed   | d may be adjusted based on fi       | nal coverage amount.         |
| • I | Read this notice and decide if you agree to<br>Choose an option below about whether to | be financially responsible for the estimated receive the items listed in Section B above. in 5 calendar days via email, fax, or mail to the ption checked. |                                     |                              |
| S   | Section C: Options—Check only one  | e box. We cannot choose a box for yo   | u.                                  |                              |
|     |  | marked above to be performed. I understand   |                                     | t expected to pay for these  |
|     | ☐ I would like to set up a payment plan  | for \$a month.**   |                                     |                              |
|     |  | ive, but <b>do not</b> bill my insurance. I understar<br>ounts may apply to the services listed above  |                                     | =                            |
|     | Option 3 — I do not want the laboratory<br>No test will be performed and my plan w     | test(s) marked above to be performed. I und ill not be billed.   | derstand with this choice I am      | not responsible for payment  |
| Pat | ient can contact the Billing department at   | 888-210-9264 to discuss payment options.   | For non-billing questions, call     | 855-488-8750.                |
| **Y | our first invoice will include the full balance due                                    | . If your payment plan is approved, you will receiv  | ve another invoice that reflects yo | ur requested payment amount. |
| Sig | nature:  |  | / Date:                             |                              |
| Ple |  |  |                                     |                              |
|     |  | Email this form to:  | / Fax this for                      | m to:                        |

www.LabCorp.com



# Step 2: Uveal Melanoma Prognostic Genetic Test Sample Requirements

U.S. insurance patients: a completed Form 1c: U.S. Insurance Information must be provided.

#### Kit includes:

- One tube with cell lysis for tumor sample
- One tube with cell lysis for buccal swab sample
- One sterile cytology brush for buccal swab collection
- Plastic bag to place samples in
- · Absorbent pad for shipping
- Rigid box for shipping
- Patient lables

#### Samples required (both required):

- Normal sample: buccal swab or blood sample
- Tumor sample: tumor biopsy (FNAB or other)

### Sample Preparation Instructions

#### Normal sample:

• Blood samples for DNA: 10 mls venous blood in yellow-topped ACD tubes or lavender-topped EDTA tubes at room temperature, to be received within 5 days after draw.

Or

#### • Buccal swab:

- Do a gentle mouth rinse with water to clear the mouth of debris.
- Scrape the inside of the patient's mouth using ten strokes with the collection brush (provided). Either cheek is fine.
- Eject the tip by firmly pressing the plunger at the end of the handle into the provided tube labelled **Buccal** (provided).
- Label the tube with one of the stickers (provided), complete with the patient name and date of birth.
- Once the buccal sample is in the tube, seal tube with twist top cap, it can be stored at <u>room temperature</u> or refridgerated (4°C or 39°F) until shipping.
- Place the tube in the plastic bag and rigid container (provided).

#### Tumor sample:

• FNAB: Place the FNAB sample in the collection tube (provided). Two or more FNAB passes are preferred and all passes can be combined in one tube.

Or

- **Biopsy**: If possible, larger tumor tissue samples from a biopsy are preferred. Place the fresh tumor sample in the collection tube (provided). **DO NOT FIX** the tissue.
- Label the tube with one of the stickers (provided), complete with the patient name and date of birth.
- Once the tumor sample is in the tube, seal tube with twist top cap. Tube can be regridgerated stored (4°C or 39°F) until shipping.
- Place the tube in the plastic bag and rigid container (provided). Leave the absorbent pad in the plastic bag



# Step 3: Shipping Requirements

Multiple separated samples may be shipped in one box. Place multiple biohazard bags containing labeled samples into one box. Multiple boxes can be shipped in one courier envelope.

## **Shipping Instructions**

- Ship samples to Impact Genetics at address shown on this page using a courier envelope.
- Include Uveal Melanoma Informed Consent and Requisition Forms (1a and 1b) with the samples. Patients in the U.S. must also include U.S. Insurance Information (Form 1c) if required and not provided previously.
- Complete appropriate Air Waybill. If you cannot use FedEx or Purolator, please contact us.
- Place Air Waybill in the document pouch.
- For samples from outside of Canada, complete and sign appropriate customs forms (provided and available on our website; phone us if help is required). Place the customs forms in the document pouch.
- Within Canada, use **Purolator Express** (next-day) or **FedEx Priority** service (next-day). Outside of Canada use **FedEx Priority** service (next-day) and **use a FedEx "Clinical Pak"**. If you cannot use Purolator or FedEx, please contact us.
- Provide us with the parcel tracking number soon after courier pick-up: 647-478-4902, info@impactgenetics.com.
- For emailed PDF FedEx waybills and customs forms, please contact us directly.

## Send to Impact Genetics

mail: Impact Genetics 115 Midair Court Brampton, ON L6T 5M3

tel: 1-877-624-9769 fax: 905-697-9786